Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.
Christoforidou
A
A
Department of Haematology, Democritus University of Thrace, Alexandroupolis, Greece. annachristof@yahoo.gr
Pantelidou
D
D
Anastasiadis
A
A
Goutzouvelidis
A
A
Margaritis
D
D
Kotsianidis
I
I
Spanoudakis
E
E
Kaloutsi
V
V
Bourikas
G
G
Tsatalas
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000188:drug therapy*; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects; D013920:Thrombocythemia, Essential / Q000188:drug therapy*
D011799:Quinazolines; C021139:anagrelide; D006918:Hydroxyurea